Allied Market Research

U.S. Cardiac Resynchronization Therapy Market Expected to Reach $983.3 Million by 2027


Report Code : A10292

quote The presence of favorable reimbursement policies, rise in investments, increase in technological advancements, and a growth in sedentary lifestyle among the U.S. population makes way for the growth of the cardiac resynchronization therapy market in the U.S. In addition, U.S. healthcare spending grew 4.6% in 2019 (as compared to 2018), reaching $3.8 trillion or $11,582 per person is expected to assist in the market growth over the forecast period. quote

Kishor Sherkar
Lead Analyst, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, “U.S. Cardiac Resynchronization Therapy Market, by Type, Application, and End User: Opportunity Analysis and Industry Forecast, 2020–2027,” the U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.

Cardiac resynchronization therapy (CRT) also known as biventricular pacing or multisite ventricular pacing, is a type of treatment to help correct serious heart rhythm problems. It involves simultaneous pacing of the right ventricle (RV) and the left ventricle (LV). CRT devices assist heart beat efficiently and monitor heart condition, thereby the healthcare professional can provide proper treatment to the patient. Cardiac resynchronization therapy helps in restoring mechanical synchrony by electrically activating the heart in a synchronized manner.

Growth in aging population, rise in sedentary lifestyle along with surge in prevalence of cardiovascular diseases (CVDs), increase in technological developments in the CRT pacemakers and CRT defibrillators, the presence of advanced healthcare infrastructure, and surge in healthcare expenditure in the U.S. are expected to drive the market growth during the forecast period. For instance, in 2016, first, as well as second-generation products of the CRT market were available. In addition, the third-generation products is underway and Medtronic plc has become a pioneer in the CRT market by receiving a United States Food and Drug Administration (USFDA) approval for two MRI-Safe CRT-D devices in 2016. The third-generation products will facilitate MRI testing of patients implanted with CRT devices without incurring any complications or fatalities in the near future. However, high cost of CRT therapy and the presence of rigorous regulations for CRT devices in the U.S. are anticipated to hinder the market growth during the forecast period.

The U.S. cardiac resynchronization therapy market is segmented into type, application, and end user. By type, the market is categorized into CRT pacemaker and CRT defibrillator. The CRT defibrillator segment dominated the market in 2019, and is expected to continue this trend over the forecast period owing to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.

By application, the U.S. cardiac resynchronization therapy market is classified into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. According to a study published in the National Center for Biotechnology Information (NCBI), the incidence of Intraventricular dyssynchrony was high among patients presenting with left bundle branch block. Thereby, supporting the dominance of the intraventricular dyssynchrony segment in 2019 in terms of revenue.

By end user, the U.S. cardiac resynchronization therapy market is segregated into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. The hospitals segment is anticipated to lead the market during the assessment period as hospitals are the primary point for diagnosis and treatment of cardiovascular diseases.

Market participants are implementing growth strategies, namely, new product launches, mergers and acquisitions (M&As), and partnerships and collaborations to gain a competitive advantage. For instance, in February 2017, Boston Scientific Corporation launched the RESONATE cardiac resynchronization therapy defibrillator systems in Europe, featuring SmartCRT technology, indicated for heart failure patients across Europe.

The key players functioning in the U.S. cardiac resynchronization therapy market are Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.

Key Findings Of The Study

  • On the basis of type, the CRT defibrillator segment was the highest contributor to the U.S. cardiac resynchronization therapy market in 2019
  • On the basis of application, the intraventricular dyssynchrony segment dominated the U.S. cardiac resynchronization therapy market in 2019, and is expected to continue this trend during the forecast period.
  • On the basis of end user, the specialized cardiac treatment centers segment is anticipated to register fastest CAGR during the forecast period

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975



For Media Inquiries, Please Contact

Tushar Nagose
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote U.S. Cardiac Resynchronization Therapy Market by Type (CRT Pacemaker and CRT Defibrillator), Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, and Atrioventricular Dyssynchrony), and End User (Hospitals, Ambulatory Surgical Centers, and Specialized Cardiac Treatment Centers): Opportunity Analysis and Industry Forecast, 2020–2027 quote

View Report
Avenue Video Loading...

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 3,552 niche industries and company profiles on more than 12,953 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.


Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Published Date Jan 2021

Surgical Equipment Market

Download Sample

Published Date Nov 2020

Medical Implant Market

Download Sample

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"U.S. Cardiac Resynchronization Therapy Market"
Purchase Enquiry